Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Flamingo Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...
Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology
Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement ...